Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

CNBC’s Jim Cramer on Thursday thought it worthwhile to review ten stocks that led the Dow Jones Industrial Average over the ...

Amgen, one of the largest biotechnology companies in the world, delivered a solid fourth-quarter earnings beat in both top and bottom line numbers as well as issued solid guidance for 2025, but some ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...